Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (71-80 of 791) with videos related to

Pageof 80
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|May 15, 2015
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigmElias Jabbour, Hagop Kantarjian, Jorge Cortes
Lancet (London, England)|August 23, 2021
Chronic myeloid leukaemiaJorge Cortes, Carolina Pavlovsky, Susanne Saußele
Targeted Oncology|April 4, 2009
Treatment selection after imatinib resistance in chronic myeloid leukemiaElias Jabbour, Jorge Cortes, Hagop Kantarjian
The Lancet. Oncology|May 14, 2013
Is there a standard induction regimen for patients with AML?Farhad Ravandi, Jorge Cortes, Hagop Kantarjian
Expert Opinion on Drug Safety|November 28, 2023
A comparative safety review of targeted therapies for acute myeloid leukemiaMark Dalgetty, Christian Leurinda, Jorge Cortes
Current Opinion in Oncology|September 22, 2006
Novel tyrosine kinase inhibitors in chronic myelogenous leukemiaElias Jabbour, Jorge Cortes, Hagop Kantarjian
Nature Medicine|January 9, 2007
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'Ehab Atallah, Hagop Kantarjian, Jorge Cortes
Seminars in Hematology|September 30, 2010
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?Elias Jabbour, Hagop Kantarjian, Jorge Cortes
Core Evidence|August 10, 2010
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based reviewElias Jabbour, Jorge Cortes, Hagop Kantarjian
Current Treatment Options in Oncology|April 11, 2013
Chronic myeloid leukemia: overview of new agents and comparative analysisPreetesh Jain, Hagop Kantarjian, Jorge Cortes
Pageof 80

Showing results (71-80 of 791) with videos related to

Sort By:
Pageof 80
Clinical Lymphoma, Myeloma & Leukemia|May 15, 2015
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigmElias Jabbour, Hagop Kantarjian, Jorge Cortes
Lancet (London, England)|August 23, 2021
Chronic myeloid leukaemiaJorge Cortes, Carolina Pavlovsky, Susanne Saußele
Targeted Oncology|April 4, 2009
Treatment selection after imatinib resistance in chronic myeloid leukemiaElias Jabbour, Jorge Cortes, Hagop Kantarjian
The Lancet. Oncology|May 14, 2013
Is there a standard induction regimen for patients with AML?Farhad Ravandi, Jorge Cortes, Hagop Kantarjian
Expert Opinion on Drug Safety|November 28, 2023
A comparative safety review of targeted therapies for acute myeloid leukemiaMark Dalgetty, Christian Leurinda, Jorge Cortes
Current Opinion in Oncology|September 22, 2006
Novel tyrosine kinase inhibitors in chronic myelogenous leukemiaElias Jabbour, Jorge Cortes, Hagop Kantarjian
Nature Medicine|January 9, 2007
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'Ehab Atallah, Hagop Kantarjian, Jorge Cortes
Seminars in Hematology|September 30, 2010
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?Elias Jabbour, Hagop Kantarjian, Jorge Cortes
Core Evidence|August 10, 2010
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based reviewElias Jabbour, Jorge Cortes, Hagop Kantarjian
Current Treatment Options in Oncology|April 11, 2013
Chronic myeloid leukemia: overview of new agents and comparative analysisPreetesh Jain, Hagop Kantarjian, Jorge Cortes
Pageof 80